Genome-scale analysis identifies novel transcript-variants in esophageal adenocarcinoma by Purkayastha, B P D et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
1-1-2020 
Genome-scale analysis identifies novel transcript-variants in 
esophageal adenocarcinoma 
B P D Purkayastha 
Case Western Reserve University 
E R Chan 
Case Western Reserve University 
D Ravillah 
Case Western Reserve University 
L Ravi 
Case Western Reserve University 
R Gupta 
Case Western Reserve University 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Recommended Citation 
Purkayastha, B P D; Chan, E R; Ravillah, D; Ravi, L; Gupta, R; Canto, M I; Wang, J S; Shaheen, N J; Willis, J E; 
Chak, A; Varadan, V; and Guda, K, ,"Genome-scale analysis identifies novel transcript-variants in 
esophageal adenocarcinoma." Cellular and Molecular Gastroenterology and Hepatology.,. . (2020). 
https://digitalcommons.wustl.edu/open_access_pubs/9604 
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been 
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. 
For more information, please contact engeszer@wustl.edu. 
Authors 
B P D Purkayastha, E R Chan, D Ravillah, L Ravi, R Gupta, M I Canto, J S Wang, N J Shaheen, J E Willis, A 
Chak, V Varadan, and K Guda 








arising from aberrant RNA splicing
and/or processing, can play a functional
role in tumor pathogenesis1 and are
attractive as biomarkers and targets for
cancer therapy. To date, the prevalence
and significance of such alternative
transcript isoforms in esophageal
adenocarcinoma (EAC), an increasingly
prevalent and lethal malignancy,2
remain unknown. Here, using an
agnostic genome-scale approach, we




(RNAseq) was performed on a discovery
sample set of 49 treatment-naive EAC
and 40 normal/premalignant fresh-
frozen biopsy tissues (Supplementary
Table 1 and Supplementary Methods),
followed by de novo transcriptome
analysis to specifically identify novel/
unannotated gene transcript-variants
primarily induced in EACs but not in
normal/premalignant tissues. Following
stringent and orthogonal evaluation us-
ing transcript-variant specific polymer-
ase chain reaction (PCR) in respective
primary EAC tumors, we identified 7
novel candidate EAC-associated
transcript-variants (Supplementary
Figure 1, Supplementary Table 2).
Together, the 7 candidate transcript-
variants accounted for 71% of EACs
tested, with each of the transcript-
variants being induced in 10%–30% of
EACs in the RNAseq discovery cohort.
We subsequently prioritized a
novel transcript-variant of the collagen
X alpha 1 chain precursor (COL10A1)
gene for further studies, on the basis of
the recognized pro-tumorigenic role of
COL10A1 pathway network in other
tumor contexts.3–8 Using bidirectional
rapid amplification of cDNA ends
(RACE) analysis, we first characterized
the full-length transcript structure of
this novel COL10A1-variant, hereafter
referred to as COL10A1Var1 (deposited
Figure 1. Characterization of
COL10A1Var1. (A) Shown are the
50 to 30 exon (Ex)-introns (thin line)
structures of COL10A1Var1 and
canonical COL10A1. UTR, un-
translated region. (B) Western blot
analyses depicting COL10A1Var1
and COL10A1 proteins. IB, immu-
noblotting; IP, immunoprecipita-
tion. CEMIP1 was used as positive
control for secreted protein and
Empty vector as a negative con-
trol. (C) Pie charts demonstrating
the proportion (%) of samples
positive for COL10A1Var1 tran-
script (top, red color) or canonical
COL10A1 (bottom, blue color) in
respective SQ, GAST, BM, HGD,
and malignant (EAC) tissue bi-
opsies. ***P< .0001 indicates sig-
nificant difference in the
proportion COL10A1Var1 positivity
between malignant (EAC) vs any of
the respective non-EAC tissue
groups, estimated by using a one-
tailed Fisher exact test.
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in GenBank: MN308081). COL10A1Var1
is a 3-exon transcript (3444 base pairs
[bp]), containing a longer and distinct
50 exon compared with the canonical
(NM_000493.4) transcript (Figure 1A,
Supplementary Figure 1). In silico an-
alyses (NCBI ORFfinder) predicted
COL10A1Var1 to encode for a w66 kDa
(680 aa) protein, identical in size to the
secreted canonical COL10A1 protein,
which we confirmed by using orthog-
onal immunoprecipitation and West-
ern blot analyses upon transfecting
HEK293T cells with full-length
COL10A1Var1 transcript (3444 bp), or
the coding sequence of canonical
COL10A1 transcript (Figure 1B).
Using a robust quantitative real-
time PCR (qPCR) assay that specif-
ically detects COL10A1Var1 but not the
canonical transcript, we next evaluated
the generality and frequency of
COL10A1Var1 expression in a validation
cohort (N ¼ 832) consisting of
treatment-naive EAC (N ¼ 170), Bar-
rett’s metaplasia (BM) (N ¼ 123), Bar-
rett’s with high grade dysplasia (HGD)
(N ¼ 60), normal esophageal squamous
(SQ) (N ¼ 465), and normal gastric
(GAST) (N ¼ 14) biopsy tissues
(Supplementary Table 1). Our orthog-
onal analysis demonstrated COL10A1-
Var1 to be robustly induced in the
majority (w60%) of EACs (Figure 1C,
Supplementary Table 3). In striking
contrast to EAC, only a minority of BM,
HGD, SQ, and GAST samples tested
positive for COL10A1Var1 (Fisher exact
test, P < .0001; Figure 1C,
Supplementary Table 3). We also note
that COL10A1Var1 is a more frequently
detected isoform in EACs, as compared
with the canonical COL10A1 transcript
that was detected in approximately
one-fourth of EAC samples with no
marked differences between EAC and
normal/premalignant tissues
(Figure 1C, Supplementary Table 3).
Taken together, these findings strongly
point to COL10A1Var1 as a recurrently
induced transcript-variant in advanced
stages of EAC development.
Because fibrillary protein networks
(collagen, elastin) and glycoproteins
(fibronectin) play a vital role in facili-
tating migration and invasion of cancer
cells,9 we next evaluated the impact of
COL10A1Var1 knockdown on the
migratory potential of EAC cells in a
durotaxis10 assay. We note that the
EAC cell lines positive for COL10A1Var1
also expressed canonical COL10A1
transcript (Figure 2A), and repeated
attempts to specifically knockdown
COL10A1Var1 with custom short hairpin
RNAs (shRNAs) proved technically
unsuccessful. Nonetheless, because
both COL10A1Var1 and canonical
COL10A1 transcripts code for identical
protein (Figure 1B) and consequently
may exhibit similar function, as an
alternative approach we used well-
characterized COL10A1 shRNAs that
also target COL10A1Var1 for subsequent
studies. OE19 EAC cells (Figure 2A),
stably expressing control or COL10A1
shRNAs under the control of doxycy-
cline (Figure 2B), were seeded onto
one-half of a glass coverslip coated
with fibronectin alone (representing
soft surface). Migration (durotaxis) of
cells from the soft surface to an adja-
cent fibronectin-coated hydrogel
(stiffer, 12 kPa) surface was monitored
over time in the presence of doxycy-
cline. Loss of COL10A1Var1/COL10A1
indeed significantly impeded the dur-
otactic ability of EAC cells (P < .004)
(Figure 2C), suggesting COL10A1 iso-
forms as potential regulators of
mechanosensing ability of EAC cells.
Taken in toto, we identify
COL10A1Var1 as a novel and recurrent
EAC-associated transcript-variant
with a potential pro-tumorigenic
function. On a broader scale, our
study represents the first genome-
wide analysis identifying novel
transcript-variants induced in EAC.
Figure 2. Impact of COL10A1/Var1
on durotaxis of EAC cells. (A)
PCR-based analysis showing
COL10A1Var1 and canonical
COL10A1 expression in normal
esophageal squamous (Epc2),
non-dysplastic BE (CP-A),
dysplastic BE (CP-B, CP-C, CP-
D), and EAC (OE19, OE33, FLO-1,
EsoAd1, SKGT4) cell lines. B2M
was used as the internal RNA
control. BE, Barrett’s esophagus.
(B) Representative images (left)
demonstrating shRNA induction
on doxycycline (Dox) treatment in
stable OE19 cells, carrying either
non-targeting control shRNA or
shRNAs targeting both
COL10A1Var1 and canonical
COL10A1 transcripts (depicted as
COL10A1/Var1). Note the specific
induction of TurboRFP, a red
fluorescent reporter of shRNA in-
duction, on doxycyline treatment
in these cells. PCR analysis (right)
demonstrating knockdown of COL10A1/Var1 RNA on doxycycline treatment of the stable OE19 cells. B2M was used as an internal RNA control. (C)
Representative images of durotaxis assay in stable OE19 cells. Quantitative analysis of cell migration (bar graph), measured as total fluorescence units
(TFU, Y-axis) of TurboRFP-positive cells in the stiffer surface. All data are plotted as mean ± standard error of the mean, obtained from 3 replicate
experiments. **P < .004 indicates significant differences in COL10A1/Var1 knockdown vs control shRNA cells, estimated by using a Student t test
assuming unequal variances.
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Further comprehensive studies are
warranted to decipher the biologic
role of the identified candidates and
to evaluate their utility as biomarkers
and therapeutic targets in this
increasingly prevalent and lethal
malignancy.
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Supplementary Methods
Patient Samples
We compiled an in-house whole-tran-
scriptome RNA sequencing (RNAseq)
dataset previously generated by our
group1,2 for discovery studies and an
independent validation cohort (N ¼
832) consisting of treatment-naive
malignant, premalignant, and nonma-
lignant biopsy tissues (Supplementary
Table 1). All samples were accrued
with informed consent under an insti-
tutional review board approved pro-






Briefly, RNAseq reads that passed
quality control were aligned to the
human reference genome
(GRCh37p13) using the STAR aligner
v2.5.1. The resulting bam files were
sorted for de novo transcriptome as-
sembly using Cufflinks in addition to
the Gencode transcriptome annotation
for GRCh37 version 19 as a guide. The
resulting final merged transcriptome
assembly was compared with the
reference annotation from Gencode
using Cuffcompare. Of note, the detec-
tion of any transcript, including novel
transcripts, in the de novo tran-
scriptome assembly was required to be
supported by a minimum of 10 paired-
reads. Novel transcripts were further
examined visually to confirm the
presence of supporting reads spanning
the novel junctions using the Integra-
tive Genomics Viewer (IGV). Subse-
quent experimental validations of
these junctions were performed by




One microgram of total RNA was
reverse-transcribed by using Super-
script III First-Strand Synthesis (Life
Technologies, Carlsbad, CA; #18080).
Quantitative PCR analysis was per-
formed by using iQ SYBR Green
Supermix system (Bio-Rad Labora-
tories, Hercules, CA; #170-8887) with
custom intron-spanning primer set for
COL10A1Var1 (Supplementary Table 2)
or commercially available primer set
for canonical COL10A1 transcript
(Qiagen, Hilden, Germany). B2M was
used as an endogenous RNA control as
previously described by our group.2
Each qPCR reaction was carried out
in triplicate in a 25 mL volume for 50
cycles using a Bio-Rad CFX96 Real-
Time PCR machine. Samples were
designated positive for COL10A1 tran-
script isoforms using respective melt-
curve signals in the qPCR assay.
Representative qPCR products were
further subjected to direct Sanger
sequencing for additional confirmation
of transcript isoforms. A negative
sample indicates no signal in a 50-cycle
qPCR assay.
Rapid Amplification of cDNA
Ends
We obtained the full-length sequence
of the novel transcript-variant,
COL10A1Var1, through RACE in OE19
EAC cell line using the SMARTer RACE
cDNA kit (Takara Bio, Kusatsu, Shiga,
Japan; #634860). The RACE products
were purified, cloned into TOPO TA
vector (ThermoFisher Scientific, Wal-
tham, MA), and subsequently
confirmed by Sanger sequencing.
Cell Culture and Transfection
EAC and premalignant Barrett’s
esophagus cell lines were cultured as
previously described by our group.1,2
HEK293T cells were transfected with
pcDNA3.1 vector containing either
FLAG-tagged canonical COL10A1 ORF
(GenScript USA Inc, Piscataway, NJ;
#OHU18227D), full-length COL10A1-
Var1, empty vector (negative control),
or with CEMIP 3 (positive control for
secreted protein) using Lipofectamine
2000 (Life Technologies; #11668019).
Immunoprecipitation and
Immunoblotting
Cell culture supernatants were trans-
ferred to an Amicon Ultra-4 10K filter
column (Millipore, Burlington, MA;
#UFC801024), concentrated by centri-
fugation at 4000g for 15 minutes,
immunoadsorbed overnight at 4C us-
ing anti-FLAG antibody conjugated
agarose beads (Sigma-Aldrich, St.
Louis, MO; #A2220), and washed with
RIPA buffer (150 mmol/L NaCl, 25
mmol/L Tris [pH 7.4], 0.1% sodium
dodecyl sulfate, 1% NP-40). The
immunoprecipitated proteins were
subjected to electrophoresis on 4%–
12% polyacrylamide gel (Life Tech-
nologies; #0321) and transferred to
Hybond–C Extra nitrocellulose mem-
brane (GE Healthcare, Chicago, IL;
#10600016). Membranes were blocked
with5%milk inTBST (0.05%Tween-20
in Tris buffered saline) and incubated
overnight at 4C with either horse-
radish peroxidase–conjugated anti-
FLAG antibody (Cell Signaling Technol-
ogy, Danvers, MA; #2044S) or anti-
COL10A1 (Abcam, Cambridge, UK;
#ab182563) primary antibody at
1:1000 dilution. For COL10A1, blots
were incubated with anti-rabbit horse-
radish peroxidase secondary antibody
(Cell Signaling Technology; #7074) at
1:5000 in 5% milk in TBST. Chem-
iluminescence was visualized by using
ECL-Plus Western Blotting Detection
Kit (GE Healthcare; #RPN2232).




viral vectors, containing nonoverlap-
ping shRNAs targeting different regions
of COL10A1/Var1 transcript (Dharma-
con, Lafayette, CO; #V3SH11252-
227571902, #V3SH11252-228435149)
or non-targeting shRNA (Dharmacon;
#VSC11655), were produced in
HEK293T cells using standard proced-
ures, and viral titers were analyzed by
using a 24-gag ELISA kit (Takara;
#632200). OE19 EAC cells were infec-
ted with the viral particles and treated
with puromycin (500 ng/mL) for sub-
sequent stable cell line generation.
Induction of shRNAs on doxycyline
(0.6 mg/mL) treatment was confirmed
by TurboRFP signal under fluorescent
microscope, and knockdown of
COL10A1/Var1 was confirmed by qPCR
with isoform-specific primers. At least 3
independently derived clones per
shRNA were used for the study.
These lentiviral-based shRNAs were
used in the durotaxis assay as described
below.
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Durotaxis Assay
Durotaxis assay was performed
following protocol of Wen et al4 with
some modification. Cells were seeded
onto one-half of 18 mm2 glass cover-
slip coated with fibronectin alone
(representing soft surface), whereas
the second-half of the glass coverslip
contained a fibronectin-coated poly-
acrylamide hydrogel, representing the
stiffer (12 kPa) surface. Briefly, the
coverslip was functionalized by using
3-(trimethoxysilyl) propyl methacry-
late (Millipore Sigma; #440159) to
facilitate covalent attachment of
hydrogel substrates to glass surface. A
polymer solution containing acryl-
amide monomers (Millipore Sigma;
#A7802), cross-linker N,N methylene-
bis-acrylamide, ammonium persulfate
(Millipore Sigma; #A3678), and
N,N,N0,N0-tetramethylethylenediamine
(TEMED) (Bio-Rad; #1610801) was
prepared and allowed to polymerize on
one-half of the glass coverslips. The
6.1% acrylamide was used to obtain the
12 kPa of hydrogel stiffness. The gels
were sterilized through ultraviolet
exposure for 2  30 minutes. To allow
for cell adhesion and fibrous-protein




#803332), activated with ultraviolet
light exposure for 2  5 minutes, fol-
lowed by 1 phosphate-buffered saline
wash for 3 times. The entire glass cov-
erslips were then incubated in fibro-
nectin (ThermoFisher Scientific;
#PHE0023) overnight, followed by
normalization with cell culture medium
for at least 2 hours. The 1  104 OE19
EAC cells, expressing COL10A1/Var1
shRNAs or control shRNA (see above),
were seeded on one-half of the coverslip
with the fibronectin-coated glass sur-
face and allowed them to grow over-
night. Subsequently, the cells were
treatedwith 10% (Tet-free) fetal bovine
serum supplemented culture media
with or without doxycycline (0.6 mg/
mL). Experiments were performed
in triplicates, and the fluorescent sig-
nals were captured and measured over
time with Keyence BZ-X800 (Osaka,
Japan) fluorescence microscope and




1. Blum AE, et al. Cancer Res 2016;
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Supplementary Figure 1. Full-length structure of novel transcript-variants identified in EACs. Shown are the complete
mRNA sequences (50 to 30) of the respective candidate transcript-variants discovered in EACs. For each of the 7 candidates,
variant-specific sequences are highlighted in blue font. Shown below each of the sequences are positions of individual exons
and coding sequence. For each of the variants and their corresponding canonical genes, exon-intron structures along with
their relative sizes-distances are illustrated on the right.
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
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distribution Cancer stage distribution
EACa 49 65 (36 - 88) 89% (male)
11% (female)
Stage I (17.9%), Stage II

























distribution Cancer stage distribution
EACd 170 64 (34–89) 77% (male)
15% (female)
Stage I (14.1%), Stage II























a11% of EACs were gastroesophageal junctional adenocarcinomas.
bMedian surveillance of 9 years, ranging from 6 to 22 years.
cEach of the 11 normal SQ samples was obtained from respective EAC patients included in the RNA sequencing.
d13% of EACs were gastroesophageal junctional adenocarcinomas.
eClinical follow-up information unavailable (progression status unknown) for these patients.
654.e14 Purkayastha et al Cellular and Molecular Gastroenterology and Hepatology Vol. 10, No. 3
Downloaded for Anonymous User (n/a) at Washington University in Saint Louis Bernard Becker Medical Library from ClinicalKey.com by Elsevier on October 08, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.




































chr6 116440086 116443124 – 3 3038
COL10A1Var1 chr6 116446502 116446670 – 2 168 3442 252..2294 680
chr6 116479777 116480013 – 1 236
chr6 39063820 39073552 – 3 9732
SAYSD1Var1 chr6 39077090 39081496 – 2 4406 14523 4788..5138 116
chr6 39082659 39083044 – 1 385
chr5 68462688 68463110 þ 1 422
chr5 68463735 68463905 þ 2 170
chr5 68464000 68464170 þ 3 170
CCNB1Var1 chr5 68467097 68467279 þ 4 182 1643 403..1512 369
chr5 68470078 68470236 þ 5 158
chr5 68470704 68470940 þ 6 236
chr5 68471224 68471529 þ 7 305
chr2 73300510 73302852 – 5 2342
chr2 73303121 73303310 – 4 189
RAB11FIP5Var1 chr2 73306779 73308473 – 3 1694 5700 144..3566 1140
chr2 73315178 73315877 – 2 699
chr2 73316007 73316783 – 1 776
chr18 77889764 77890260 þ 1 496
ADNP2Var1 chr18 77890986 77891075 þ 2 89 5369 765..3785 1006
chr18 77893495 77898279 þ 3 4784
chr16 46989335 46989534 – 10 199
chr16 46990919 46991132 – 9 213
chr16 46992915 46993042 – 8 127
chr16 46993187 46993331 – 7 144
DNAJA2Var1 chr16 46998523 46998719 – 6 196 1857 407..1645 412
chr16 47001425 47001558 – 5 133
chr16 47001996 47002076 – 4 80
chr16 47005261 47005484 – 3 223
chr16 47005808 47005867 – 2 59
chr16 47007406 47007889 – 1 483
chr14 54941202 54944877 – 3 3675
GMFBVar1 chr14 54946504 54946577 – 2 73 3996 270..395 41
chr14 54947592 54947840 – 1 248
aPutative candidate transcript–variant coding regions were predicted using NCBI ORF finder. Listed are only those predicted
ORFs for transcript–variants that are in the same reading frame as respective canonical transcripts.
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GMFB 2764 NM_004124 4085 54..482 NP_004115 142
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Supplementary Table 3.Expression Status of COL10A1Var1 and Canonical COL10A1 Across Lesions
EAC (N ¼ 219)a
Canonical COL10A1-positive Canonical COL10A1-negative
COL10A1Var1-positive 53 (24.2%) 79 (36.07%)
COL10A1Var1-negative 1 (0.46%) 86 (39.27%)
NDBE (N ¼ 141)a
Canonical COL10A1-positive Canonical COL10A1-negative
COL10A1Var1-positive 0 (0%) 2 (1.42%)
COL10A1Var1-negative 22 (15.6%) 117 (82.98%)
HGD (N ¼ 60)a
Canonical COL10A1-positive Canonical COL10A1-negative
COL10A1Var1-positive 1 (1.67%) 1 (1.67%)
COL10A1Var1-negative 5 (8.33%) 53 (88.33%)
SQ (N ¼ 476)a
Canonical COL10A1-positive Canonical COL10A1-negative
COL10A1Var1-positive 9 (1.89%) 21 (4.41%)
COL10A1Var1-negative 67 (14.08%) 379 (79.62%)
GAST (N¼ 25)a
Canonical COL10A1-positive Canonical COL10A1-negative
COL10A1Var1-positive 0 (0%) 1 (4%)
COL10A1Var1-negative 9 (36%) 15 (60%)
NDBE, nondysplastic Barrett’s esophagus.
aNumber of samples combined from both Discovery and Validation cohorts.
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